The Prothrombotic Predominance in Metabolic Syndrome: A Complex Patomechanism

Fahmy Rusnanta, Mohammmad Saifur Rohman


Patients with metabolic syndrome (MS) have many cardiovascular complications related to atherothrombotic complications. MS contributes premature atherosclerosis, increase platelet activation, promote coagulation factors, and reduce fibrinolytic activity. The last step in the atherotrombotic cascade is blood clot formation, and altered clot structure is a key role to determine cardiovascular complications. This review discusses imbalance of hemostasis and eludicate their role of increased propensity to CVD. The correlation of MS and fibrinolysis is reviewed and complex mechanisms that promote coagulation are discussed. Understanding these effects on hemostasis pathway helps to build more effective treatment and preventive strategies to diminish the complication in this condition. 


metabolic syndrome, thrombosis, fibrinolysis, blood clot, cardiovascular disease

Full Text:



Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vluksan V, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation. 2003;108:420-5.

Grundy S. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002;105:2696-8.

Tsai AW, Cushman M, Rosamond WD, et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med. 2002;162:1182-9.

Bladbjerg EM, Stolberg CR, Juhl CB. Effects of obesity surgery on blood coagulation and fibrinolysis: a literature review. Thromb Haemost. 2020;120:579-91.

Grover SP, Mackman N. Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. Arterioscler Thromb Vasc Biol. 2018;38(04):709-25

Sidelmann JJ, Gram J, Jespersen J, Kluft C. Fibrin clot formation and lysis: basic mechanisms. Semin Thromb Hemost. 2000;26(06):605-18.

Gaffney PJ, Edgell TA, Whitton CM. The haemostatic balance – Astrup revisited. Haemostasis. 1999;29(01):58–71.

Napoleone E, DI Santo A, Amore C, et al. Leptin induces tissue factor expression in human peripheral blood mononuclear cells: a possible link between obesity and cardiovascular risk? J Thromb Haemost. 2007;5(07):1462-8.

Pergola GD, Pannacciulli N. Coagulation and fibrinolysis abnormalities. J. Endocrinol. Invest. 2002;25:899-904.

Michalska M, Iwan-Ziętek I, Gniłka W. PAI-1 and α2-AP in patients with morbid obesity. Adv Clin Exp Med. 2013;22(06): 801-7.

Lind L, Siegbahn A, Ingelsson E, Sundström J, Arnlöv J. A detailed cardiovascular characterization of obesity without the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2011;31(08):e27–e34.

Prüller F, Raggam RB, Posch V, et al. Trunk weighted obesity, cholesterol levels and low grade inflammation are main determinants for enhanced thrombin generation. Atherosclerosis. 2012; 220(01):215-8.

Kim JA, Kim JE, Song SH, Kim HK. Influence of blood lipids on global coagulation test results. Ann Lab Med. 2015;35:15-21.

Silveira A. Postprandial triglycerides and blood coagulation. Exp Clin Endocrinol Diabetes. 2001;109:S527-32.

Andersen P. Hypercoagulability and reduced fibrinolysis in hyperlipidemia: relationship to the metabolic cardiovascular syndrome. Journal of Cardiovascular Pharmacology. 1992;20(8):S29-31.

Stoep MVD, Korporaal SJA, Miranda MV. High-density lipoprotein as a modulator of platelet dan coagulation responses. Cardiovascular Research. 2014;103(3):362-71.

Mac Callum PK, Cooper JA, Martin J, Howarth DJ, Meade TW, Miller GJ. Haemostatic and lipid determinants of prothrombin fragment F1.2 and D-dimer in plasma. Thromb Haemost. 2000;83:421-6.

Oslakovic C, Krisinger MJ, Andersson A, Jauhiainen M, Ehnholm C, Dahlback B. Anionic phospholipids lose their procoagulant properties when incorporated into high density lipoproteins. J Biol Chem. 2009;284:5896-904.

Dahlback B, Villoutreix BO. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol. 2005;25:1311-20.

Zabczyk M, Hondo L, Krzek M, Undas A. High-density cholesterol and apolipoprotein AI as modifiers of plasma fibrin clot properties in apparently healthy individuals. Blood Coagul Fibrinolysis. 2013;24:50-4.

Ebara S, Marumo M, Mukai J, Ohki M, Uchida K, Wakabayashi I. Relationship of oxidized HDL with blood coagulation and fibrinolysis in patients with type 2 diabetes mellitus. J Thromb Thrombolysis. 2018;45(2):200-5.

Catena C, Zingaro L, Casaccio D, Sechi LA. Abnormalities of coagulation in hypertensive patients with reduced creatinine clearance. Am J Med. 2000;109:556-61.

Dielis AWJH, Smid M, Spronk HMH, Hamulyak K, Kroon AA, Cate HT, The prothrombotic paradox of hypertension role of the renin-angiotensin and kallikrein-kinin systems. Hypertension. 2005;46:1236-42.

Bisoendial RJ, Kastelein JJ, Levels JH, Zwaginga JJ, van den Bogaard B, Reitsma PH, Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res. 2005;96:714-6.

Ballermann BJ, Dardik A, Eng E, Liu A. Shear stress and the endothelium. Kidney Int Suppl. 1998;67:S100-8.

Pearson JD. Endothelial cell function and thrombosis. Baillieres Best Pract Res Clin Haematol. 1999;12:329-41.

Yoshizumi M, Tsuji H, Nishimura H, Masuda H, Kunieda Y, Kawano H, Kimura S, Sugano T, Kitamura H, Nakagawa K, Nakagawa M. Natriuretic peptides regulate the expression of tissue factor and PAI-1 in endothelial cells. Thromb Haemost. 1999;82:1497-503.

Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension. 1998;32:65-71.

Stegenga ME, van der Crabben SN, Levi M, de Vos AF, Tanck MW, Sauerwein HP, Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes. 2006;55:1807-12.

Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diabetes and Vascular Disease Research. 2010;7(4):260-73.

Jörneskog G, Egberg N, Fagrell B, Fatah K, Hessel B, Johnsson H, et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia. 1996;39:1519-23.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA,; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005; 112: 2735-52.

Saklayen MG. The global epidemic of the metabolic syndrome. Current Hypertension Reports. 2018;20(12):1-8.

Sigit FS, Tahapary DL, Trompet S, Sartono E, van Dijk KW, Rosendaal FR, The prevalence of metabolic syndrome and its association with body fat distribution in middle-aged individuals from Indonesia and the Netherlands: a cross-sectional analysis of two population—based studies. Diabetol Metab Syndr. 2020;12(2):1-11.

Lee MG, Jeong MH, Ahn Y, Chae SC, Hur SH, Hong TJ, Impact of the metabolic syndrome on the clinical outcome of patients with acute ST-elevation myocardial infarction. J Korean Med Sci. 2010;25:1456-61.

Kazlauskiene L, Butnoriene J, Norkus A. Metabolic syndrome related to cardiovascular events in a 10-year prospective study. Diabetol Metab Syndr. 2015;7:1-7.

Vidula H, Liu K, Criqui MH, Szklo M, Allison M, Sibley C, Metabolic syndrome and incident peripheral artery disease-the multi-ethnic study of atherosclerosis. Atherosclerosis. 2015;243:198-203.



  • There are currently no refbacks.

Copyright (c) 2021 Fahmy Rusnanta, Mohammmad Saifur Rohman

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.